MINDMAZE THERAPEUTICS HOLDING SA Total Liabilities
MINDMAZE THERAPEUTICS HOLDING SA total liabilities. Based on the latest financial reports, MINDMAZE THERAPEUTICS HOLDING SA (MMTX) has total liabilities worth CHF8.18 Million CHF (≈ $10.34 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See MINDMAZE THERAPEUTICS HOLDING SA (MMTX) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of MINDMAZE THERAPEUTICS HOLDING SA (2024–2025)
Total liabilities of MINDMAZE THERAPEUTICS HOLDING SA from 2024 to 2025. This chart illustrates how MINDMAZE THERAPEUTICS HOLDING SA's total liabilities have evolved over time, based on quarterly financial data.
MINDMAZE THERAPEUTICS HOLDING SA Competitors by Total Liabilities
The table below lists competitors of MINDMAZE THERAPEUTICS HOLDING SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sentronic International
TWO:3232
|
Taiwan | NT$503.32 Million |
|
Rockhaven Resources Ltd
V:RK
|
Canada | CA$3.60 Million |
|
GLORY HEALTH IND. HD-001
F:84R
|
Germany | €43.59 Billion |
|
Cleo Diagnostics Ltd
AU:COV
|
Australia | AU$1.14 Million |
|
V-Tac Technology Co Ltd
TWO:6229
|
Taiwan | NT$1.13 Billion |
|
Wulff-Yhtiot Oy
HE:WUF1V
|
Finland | €38.10 Million |
|
Sh E & Chemical Co. Ltd.
KO:002360
|
Korea | ₩32.21 Billion |
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
USA | $61.13 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down MINDMAZE THERAPEUTICS HOLDING SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MMTX total asset value.
Liquidity & Leverage Metrics
MINDMAZE THERAPEUTICS HOLDING SA Total Liabilities Ratios Explained
MINDMAZE THERAPEUTICS HOLDING SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MINDMAZE THERAPEUTICS HOLDING SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MINDMAZE THERAPEUTICS HOLDING SA (2024–2025)
The table below shows the annual total liabilities of MINDMAZE THERAPEUTICS HOLDING SA from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF13.19 Million ≈ $16.67 Million |
+188314.29% |
| 2024-12-31 | CHF7.00K ≈ $8.85K |
-- |
About MINDMAZE THERAPEUTICS HOLDING SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outp… Read more